The true toll of a transient ischemic attack may be found in accelerated cognitive decline
A University of Alabama at Birmingham Heersink School of Medicine-led study suggests that first-time transient ischemic ...
Too Old to Operate2d
Impact of Endothelial Dysfunction on END After AIS
The following is a summary of “Association between impaired brachial flow-mediated dilation and early neurological ...
The Lancet13d
Neuroprotection in acute ischaemic stroke: reasons for optimism?
The challenges of translating neuroprotective interventions with promising efficacy in animal studies into effective ...
Too Old to Operate2d
Stroke Outcomes After Endovascular Therapy for Medium Vessels
The following is a summary of “Endovascular Treatment of Stroke Due to Medium-Vessel Occlusion,” published in the February ...
TipRanks on MSN2d
DiaMedica Therapeutics Appoints Daniel J. O’Connor to Board
An update from Diamedica Therapeutics ( ($DMAC) ) is now available. On February 20, 2025, DiaMedica Therapeutics appointed Daniel J. O’Connor to ...
HealthDay on MSN8d
ASA: Alteplase Ups Outcomes at 4.5 to 24 Hours After Symptom Onset in Acute Ischemic Stroke
For patients with acute ischemic stroke (AIS) whose symptoms began 4.5 to 24 hours earlier, alteplase is associated w ...
Healio13d
GLP-1 may have potential to improve poststroke outcomes, prognosis
The GLP-1 liraglutide showed potential benefit in reducing stroke recurrence and improving functional outcomes after minor ...
DiaMedica Therapeutics Announces Publication of DM199’s Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced the peer-reviewed ...
DiaMedica Therapeutics publishes DM199 data in Stroke
DiaMedica Therapeutics (DMAC) announced the peer-reviewed publication entitled: “Recombinant human tissue kallikrein-1 for treating acute ...
Morningstar6d
DiaMedica Therapeutics Announces Publication of DM199’s Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke
In animal studies of acute stroke, bradykinin B2 receptor expression on brain endothelial cells in the ischemic region increased 36-fold. In this environment, newly generated bradykinin from DM199 ...